This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

3 hours ago 1

Jonathan Ponciano, The Motley Fool

Sun, March 15, 2026 astatine 6:25 PM CDT 4 min read

On February 17, 2026, Parkman Healthcare Partners disclosed a caller presumption successful EyePoint (NASDAQ:EYPT), acquiring 1,088,033 shares successful the 4th quarter.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Parkman Healthcare Partners established a caller involvement successful EyePoint by purchasing 1,088,033 shares during the 4th quarter. The quarter-end worth of the presumption accrued by $19.88 cardinal arsenic a effect of the acquisition.

This was a caller position; EyePoint represented 1.89% of Parkman’s 13F reportable AUM arsenic of December 31, 2025.
Top holdings aft the filing:
- NYSE: BSX: $47.73 cardinal (4.5% of AUM)
- NASDAQ: PODD: $40.04 cardinal (3.8% of AUM)
- NASDAQ: DXCM: $38.99 cardinal (3.7% of AUM)
- NYSE: SYK: $37.07 cardinal (3.5% of AUM)
- NYSE: CVS: $35.73 cardinal (3.4% of AUM)
As of Friday, EyePoint shares were priced astatine $13.20, up a staggering 93% implicit the past twelvemonth and good outperforming the S&P 500’s astir 20% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$13.20
Market capitalization	$1.1 billion
Revenue (TTM)	$31.37 million
Net income (TTM)	($231.96 million)

EyePoint Pharmaceuticals develops and commercializes ophthalmic products, including ILUVIEN, YUTIQ, DEXYCU, and pipeline assets specified arsenic EYP-1901 for retinal diseases.
The institution generates gross chiefly done merchandise income and strategical collaborations focused connected sustained-release cause transportation for oculus illness treatment.
Its main customers are healthcare providers and ophthalmologists treating patients with diabetic macular edema, uveitis, and different retinal conditions successful the United States, China, and the United Kingdom.

EyePoint Pharmaceuticals is simply a biotechnology institution specializing successful innovative sustained-release cause transportation systems for ocular diseases. The institution leverages proprietary technologies and strategical alliances to code unmet needs successful ophthalmology, with a absorption connected chronic and terrible retinal conditions. Its differentiated merchandise pipeline and commercialized partnerships enactment its positioning arsenic a person successful ophthalmic therapeutics.

Breakthrough medicines often make tremendous worth agelong earlier they ever scope pharmacy shelves. Investors who specialize successful healthcare cognize that the existent accidental often emerges erstwhile a institution is approaching pivotal objective data, not aft approval. That is the backdrop surrounding today.

Shares of EyePoint are booming arsenic the steadfast works connected advancing DURAVYU, a sustained-release therapy designed to dainty superior retinal diseases specified arsenic bedewed age-related macular degeneration and diabetic macular edema. Two Phase 3 trials evaluating the cause successful bedewed AMD person enrolled much than 900 patients, with topline information expected opening successful mid-2026, per the company’s latest quarterly financials. If successful, the therapy could vie successful a monolithic ophthalmology marketplace presently dominated by predominant anti-VEGF injections.

Financially, the institution remains firmly successful improvement mode. Full-year gross totaled astir $31 cardinal successful 2025, portion the institution posted a nett nonaccomplishment of astir $232 cardinal arsenic probe spending accelerated to enactment its late-stage trials. Still, EyePoint ended the twelvemonth with astir $306 cardinal successful currency and investments, capable to money operations into precocious 2027.

Read Entire Article